ALS drug gets rare second review

Matthew Perrone, AP: September 7, 2022

(This AP article was published in numerous newspapers and media outlets across the country)

A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval.

The FDA has approved only two therapies for the disease, amyotrophic lateral sclerosis, which destroys nerve cells needed for basic functions like walking, talking and swallowing. The more effective of the two drugs extends life by several months.

In a rare move, the FDA convened a second meeting of neurology advisers who narrowly voted against the company’s drug in March. The panel was reviewing new statistical analyses from Amylyx and planned to vote again on whether to recommend approval. The FDA is not required to follow’s the group’s guidance.

An internal review by FDA scientists posted ahead of the meeting struck a negative tone, concluding that the company’s updated analysis was not “persuasive” and provided “no new data.” On the other hand, the FDA’s instructions to the panel stressed the need for regulatory flexibility when considering drugs for deadly diseases.


The ALS drug review is being closely watched as an indicator of FDA’s flexibility in reviewing experimental medications for the terminally ill and its ability to withstand outside pressure.

“We’re here because there’s a lot of pressure,” said Diana Zuckerman of the nonprofit National Center for Health Research, in an interview ahead of the meeting. “FDA is going the extra mile by saying you can have another meeting, but the company responded by giving them no new data.”

Amylyx conducted one small, mid-stage trial of its drug that showed some benefit in slowing the disease, but it was plagued by missing data and other problems, according to FDA reviewers.

“The final result — for a single study — is borderline and not very statistically persuasive,” FDA statistician Tristan Massie told panelists.

The Cambridge, Massachusetts, company says follow-up data gathered after the study showed the drug extended life. Patients who continued taking the drug survived about 10 months longer than patients who never took the drug, according to a new company analysis.

But FDA scientists said that the new approach “suffers from the same interpretability challenges” as the original study.

To read the article click here.